Summit Therapeutics Inc. (SMMT)Healthcare | Biotechnology | Miami, United States | NasdaqGM
15.52 USD
-1.61
(-9.399%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 15.55 +0.03 (0.193%) ⇧ (Oct. 13, 2026, 7:36 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 2:01 a.m. EDT
Summit Therapeutics presents a classic binary biotech dilemma where the business fundamentals are currently broken by losses and negative returns, yet the catalyst potential remains intact. The company is burning significant cash with no earnings, trading at a negative forward P/E, which technically disqualifies it from being a standard long-term buy based on traditional valuation metrics. However, the balance sheet appears robust relative to debt, providing a runway to survive until the critical FDA approval decision. The options market confirms this binary nature, with heavy positioning at strikes far above the current price, betting on a successful drug approval that could re-rate the entire company. Conversely, the dense put wall suggests fear of failure or regulatory rejection. With the 52-week high still well above the current price and recent news highlighting fresh data, the stock is poised for a violent move based entirely on the upcoming regulatory verdict. Until that decision lands, the investment thesis is purely speculative on the probability of success, making it a volatile hold rather than a fundamental buy. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.176748 |
| AutoARIMA | 0.176752 |
| MSTL | 0.186481 |
| AutoTheta | 0.204852 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 9.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.110 |
| Excess Kurtosis | -1.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.236 |
| Market Cap | 12,381,074,432 |
| Forward P/E | -13.63 |
| Beta | -1.52 |
| Previous Name | Summit Therapeutics plc |
| Website | https://www.smmttx.com |
As of Oct. 10, 2026, 2:01 a.m. EDT: Speculators are positioning for extreme volatility rather than a specific directional outcome. Call Open Interest is heavily concentrated at strikes significantly above the current price (20, 25, 47), suggesting a speculative bet on a massive upside event, while Put Open Interest forms a dense wall just below the current price (15-18 range), acting as a hedge against downside risk. The implied volatility surface shows massive spikes at deep out-of-the-money strikes for both calls and puts, indicating the market prices in a binary 'all-or-nothing' scenario driven by the pending FDA decision, rather than a linear price appreciation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.21241379 |
| Address1 | 601 Brickell Key Drive |
| Address2 | Suite 1000 |
| All Time High | 36.91 |
| All Time Low | 0.66 |
| Ask | 14.55 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 8,910,380 |
| Average Daily Volume3 Month | 5,881,301 |
| Average Volume | 5,881,301 |
| Average Volume10Days | 8,910,380 |
| Beta | -1.516 |
| Bid | 12.56 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 0.794 |
| City | Miami |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.52 |
| Current Ratio | 6.958 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 16.79 |
| Day Low | 15.465 |
| Debt To Equity | 3.236 |
| Display Name | Summit Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,784,838,600 |
| Earnings Call Timestamp Start | 1,784,838,600 |
| Earnings Timestamp | 1,784,836,800 |
| Earnings Timestamp End | 1,792,440,000 |
| Earnings Timestamp Start | 1,792,440,000 |
| Ebitda | -874,670,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.389 |
| Enterprise Value | 11,710,779,392 |
| Eps Current Year | -0.83918 |
| Eps Forward | -1.1387479 |
| Eps Trailing Twelve Months | -1.11 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.5446 |
| Fifty Day Average Change | -0.024599075 |
| Fifty Day Average Change Percent | -0.0015824836 |
| Fifty Two Week Change Percent | -21.241379 |
| Fifty Two Week High | 29.23 |
| Fifty Two Week High Change | -13.709999 |
| Fifty Two Week High Change Percent | -0.46903864 |
| Fifty Two Week Low | 12.07 |
| Fifty Two Week Low Change | 3.4500008 |
| Fifty Two Week Low Change Percent | 0.2858327 |
| Fifty Two Week Range | 12.07 - 29.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,425,565,800,000 |
| Float Shares | 153,877,921 |
| Forward Eps | -1.1387479 |
| Forward P E | -13.6290045 |
| Free Cashflow | -139,678,496 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 265 |
| Fullday Change | -1.579999 |
| Fullday Change Percent | -9.223578 |
| Fullday Price | 15.55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.80891 |
| Held Percent Institutions | 0.17581 |
| Implied Shares Outstanding | 797,749,602 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida. |
| Long Name | Summit Therapeutics Inc. |
| Market | us_market |
| Market Cap | 12,381,074,432 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_11611587 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-13 |
| Net Income To Common | -856,089,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,115,003,456 |
| Number Of Analyst Opinions | 13 |
| Open | 16.76 |
| Operating Cashflow | -458,432,992 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 305 203 2034 |
| Post Market Change | 0.029999733 |
| Post Market Change Percent | 0.19329724 |
| Post Market Price | 15.55 |
| Post Market Time | 1,791,934,602 |
| Prev Name | Summit Therapeutics plc |
| Previous Close | 17.13 |
| Price Eps Current Year | -18.494246 |
| Price Hint | 2 |
| Price To Book | 19.546598 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.669 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.76471 |
| Region | US |
| Regular Market Change | -1.6099987 |
| Regular Market Change Percent | -9.398708 |
| Regular Market Day High | 16.79 |
| Regular Market Day Low | 15.465 |
| Regular Market Day Range | 15.465 - 16.79 |
| Regular Market Open | 16.76 |
| Regular Market Previous Close | 17.13 |
| Regular Market Price | 15.52 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 7,111,626 |
| Return On Assets | -1.01611 |
| Return On Equity | -1.92505 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 797,749,602 |
| Shares Percent Shares Out | 0.051599998 |
| Shares Short | 41,155,196 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 41,330,352 |
| Short Name | Summit Therapeutics Inc. |
| Short Percent Of Float | 0.26299998 |
| Short Ratio | 5.51 |
| Source Interval | 15 |
| State | FL |
| Symbol | SMMT |
| Target High Price | 43.162025 |
| Target Low Price | 11.931495 |
| Target Mean Price | 29.843475 |
| Target Median Price | 32.786755 |
| Total Cash | 690,678,016 |
| Total Cash Per Share | 0.866 |
| Total Debt | 20,384,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.351425 |
| Two Hundred Day Average Change | -0.8314247 |
| Two Hundred Day Average Change Percent | -0.050847232 |
| Type Disp | Equity |
| Volume | 7,111,626 |
| Website | https://www.smmttx.com |
| Zip | 33,131 |